IAS News and Literature Updates:
June-July 2018

From the President's Desk:

Yuji Matsuzawa

We are thrilled to announce the new Executive Board which will begin its term on January 1, 2019 and will serve until December 31, 2021.  We also welcome our three new member Societies: Iraqi Lipid Clinics Network, Kuwait 5000, and Saudi Group for Cardiovascular Prevention and Rehabilitation. The following Boards members and new members were elected and approved by the Council during the International Symposium on Atherosclerosis in Toronto, Canada in June, 2018:

> Complete Article <

     New IAS Executive Board (2019-2021)   

The IAS Nominating Committee, chaired by Philip Barter (Australia) and composed by Anne Goldberg (USA), Chris Packard (UK), and Brian Tomlinson (Hong Kong), has presented the IAS Council the final slate of the candidates to be elected during the ISA2018 congress in Toronto. The Council of the Constituent Societies has elected the future Board members during its meeting on June 11, 2018.
The new Executive Board will begin its term on January 1, 2019 and will serve until December 31, 2021.

> Read More <

    Welcome to our new Member Societies!!   


Iraqi Lipid Clinics Network



Kuwait 5000



Saudi Group for Cardiovascular Prevention and Rehabilitation




   2018 Antonio M. Gotto, Jr. Prize in Atherosclerosis Research  

The Antonio M. Gotto, Jr. Prize in Atherosclerosis Research was awarded to Dr. Daniel J. Rader, an investigator from the Perelman School of Medicine, during the XVIII International Symposium on Atherosclerosis held on June 9-12 in Toronto, Canada.
The triennial Prize, endowed by Weill Cornell Medicine and the International Atherosclerosis Society in honor of Dr. Gotto, Dean Emeritus of Weill Cornell Medicine, recognizes outstanding scientific, medical or organizational advancement in our ability to understand the causes and the development of atherosclerosis.
The award was made in recognition of Daniel’s as a leading translational scientist who has made major contributions to our understanding of lipoprotein metabolism. His work is distinguished by its clear and direct impact on the development of new therapeutic strategies to prevent coronary heart disease (CHD). Rader discovered endothelial lipase and elucidated its role in metabolism of high density lipoproteins (HDL). He developed novel methods to trace macrophage-specific RCT in mice and assess HDL function in humans. Rader also singlehandedly championed microsomal triglyceride transfer protein (MTP) inhibitors for treatment of severe hypercholesterolemia. Rader has provided important new insights into the mechanisms by which common sequence variations discovered in genome-wide association studies alter plasma lipoprotein levels. His work spans the full spectrum of translational research, extending from basic laboratory science to the development and testing of new therapeutic agents in humans.  His work has had a major impact on current strategies to prevent and treat CHD.

Press Release on the Penn Med News website

Press Release from Weill Cornell Medicine website

Photos of the Ceremony of the Gotto Prize

          Fellowships 2018 - Winners         

After the evaluation of the IAS Fellowship Review Committee of the Applications received, I am pleased to announce the selected winners of the 2018 IAS Visiting Fellowship Awards for a 3-month period of training.

> Read More <

Also included in this Newsletter:

XVIII International Symposium on Atherosclerosis
Toronto, Canada
June 9-12, 2018

Final Program
Abstract Book
Photos of the
Opening Ceremony

In the News: 
     Featured Commentaries    

Dalcetrapid and Anacetrapib Differently Impact HDL Structure and Function in Rabbits and Monkeys
By: Matthieu R Brodeur, David Rhainds and Jean-Claude Tardif

The level of cholesterol associated with high density lipoproteins (HDL-C) is inversely correlated with cardiovascular disease risk. This protection afforded by high levels of HDL-C was linked to multiple anti-atherogenic effects of HDL such as anti-inflammatory, anti-oxidative, and anti-thrombotic activities along with its main role in reverse cholesterol transport (RCT).

> View Complete Commentary <

Changes in Lipoprotein Metabolism with Potent CETP inhibition:Lessons from Human Kinetic Studies
By: John Millar and Gissette Reyes-Soffer

Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters and triglycerides among HDL and apolipoprotein B (apoB)-containing lipoproteins, (VLDL, IDL, and LDL). Genetic deficiency of CETP is associated with elevated HDL cholesterol (C) and reduced LDL-C. Similarly, potent inhibition of CETP activity raises HDL-C levels and reduces LDL-C levels.

> View Complete Commentary <

   XIX International Symposium on Atherosclerosis 2021  

         XX International Symposium on Atherosclerosis 2024 - Winner        
We are pleased to announce that after the presentation of the outstanding bids for the ISA2024 Symposium from the Russian National Atherosclerosis Society (RNAS), Emirates Cardiac Society (ECS), Lipid Association of India (LAI), and Oman Society of Lipids & Atherosclerosis (OSLA) the IAS Executive Board during its meeting held in Toronto on June 9 has selected the winner of the ISA2024: the Oman Society of Lipids and Atherosclerosis (OSLA).

 Upcoming Meetings 

August 10-11, 2018

3rd Course on Cardiovascular Risk Factors Management: From Theory to  Clinical Practice
Santiago de Chile, Chile

Email: rodrigoalonsok@gmail.com
August 17-19, 2018
3rd Lipidology Certification Course
Lipid Association of India
New Delhi, India
August 19, 2018
Ecuadorian society of Atherosclerosis and Endothelium Symposium (IAS affiliate)
Guayaquil, Ecuador
August 18-19, 2018
5th International Symposium Summit on Lipids
Lipid Association of India
New Delhi, India
October 26, 2018
IAS Chile Symposium during the Chilean Congress on Internal Medicine - The Revolution of PCSK9 Inhibitors: Dream or Reality
Santiago, Chile
For a complete listing of all Member Society Meetings and educational activities
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Amryt, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.
>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy

Emanuela Folco, PhD
Milan, Italy

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA

 Executive Director

Emanuela Folco, Ph.D.
International Atherosclerosis Society
Viale Piave 35 
20129 Milan, Italy 
Tel: +39 02 29006267
Fax: +39 02 29007018
E-mail: emanuela.folco@athero.org; info@athero.org

US Office:
International Atherosclerosis Society 
P.O. Box 650497
  Fresh Meadow, NY 11365 (USA)
E-mail: info@athero.org

You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2018 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile